While randomized controlled trials (RCTs) are the gold standard for evidence-based
medicine, they do not always reflect real-world patient populations, limiting their …

The majority of epidermal growth factor receptor (EGFR) mutations (85–90%) are exon 19
deletions and L858R point mutations of exon 21, characterized by high sensitivity to EGFR …

With the development of antitumor therapies, different treatment methods including
monotherapy and combined therapy have achieved clinical efficacy in advanced epidermal …

Simple Summary HER2+ metastatic breast cancer (MBC) is a highly prevalent type of breast
cancer owing to its resistance to conventional anti-HER2 drugs. Therefore, novel agents that …

Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Abstract The Epidermal Growth Factor Receptor (EGFR) has been targeted through the
development of selective tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAb) …

Viruses are intracellular pathogen that exploit host cellular machinery for their propagation.
Extensive research on virus-host interaction have shed light on an alternative antiviral …

Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the …

Chiral drugs usually contain chiral centers, which are present as single enantiomers or
racemates. Compared with achiral drugs, they have significant advantages in safety and …

Objectives The optimal sequence for the administration of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) for treating non‐small cell lung cancer (NSCLC) is …